Inotiv (NOTV)

Inotiv operates through two main segments: Discovery and Safety Assessment, and Research Models and Services. The Discovery and Safety Assessment segment offers nonclinical research services for small-molecule drugs, biologics, and medical technologies. These services can include pharmacology, toxicology, bioanalysis, pathology, histology, and related analytical work used to assess how a candidate behaves and whether it presents safety concerns.

The Research Models and Services segment provides animal research models and associated services used in basic research, disease modelling, drug discovery, and development programmes. These models are used by academic institutions, biopharma companies, and other research organisations to study biology and test potential interventions. This segment is the company’s largest revenue contributor, reflecting the recurring demand for research models and support services across the life-sciences market.

Inotiv’s role is distinctive because it combines laboratory testing expertise with access to specialised research models, allowing customers to outsource multiple stages of early development to one provider. Its performance is linked to research-and-development spending across healthcare and chemicals, the pace of biotech funding, regulatory expectations for safety testing, and the company’s ability to maintain scientific quality and operational compliance.